Advanced glycation: how are we progressing to combat this web of sugar anomalies in diabetic nephropathy.
Advanced glycation end products (AGEs) in diabetic nephropathy have been extensively researched over the last decade and are now firmly established as major players in this disease. The enigma remains the search for the ideal AGE inhibition therapy, which is a great challenge in the context of the structural diversity inherent to AGE chemistry. Certainly, there is a requirement to standardize measurements of circulating and tissue levels of AGEs and to characterize the pathogenic potential of specific AGE moieties. In order to develop more effective, targeted approaches to combat diabetic nephropathy, the mechanisms of action of selective AGE inhibitors and the inter-relationships of advanced glycation with other pathogenic pathways must be addressed.
Forbes
Josephine M
JM
Danielle Alberti Memorial Centre for Diabetes Complications, Wynn Domain, Vascular Division, Baker Heart Research Institute, Melbourne, Victoria 8008, Australia. Josephine.forbes@baker.edu.au
Thallas-Bonke
Vicki
V
Cooper
Mark E
ME
Thomas
Merlin C
MC
D000818:Animals; D050260:Carbohydrate Metabolism; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000378:metabolism*; D004789:Enzyme Activation / Q000502:physiology; D017127:Glycation End Products, Advanced / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D011485:Protein Binding; D011493:Protein Kinase C / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism
D017127:Glycation End Products, Advanced; D017382:Reactive Oxygen Species; D011493:Protein Kinase C